PRODUCTS

Home » Products » Metered Dose Inhaler » Ipratropium Bromide Inhaler

loading

Share to:
facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

Ipratropium Bromide Inhaler

 
【Strength】20mcg/dose×200doses
【Brand】JEWIM or OEM
【Indication】It is indicated for the regular treatment of reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD) and chronic asthma.
【Quality Standard】Current BP standard
【GMP Approval】Australia TGA GMP
【Packing】1piece/box, 300 boxes/carton
【MOQ】5000 pieces
Availability:
Product Description


【BP Name】Ipratropium Bromide Pressurised Inhalation

【Generic Name】Ipratropium Bromide Inhalation Aerosol

【Composition】The active ingredient: Ipratropium Bromide

【Storage】Store below 30°C. Protect from frost and direct sunlight.

【Package】An inhaler comprising an aluminium canister sealed with a metering valve, actuator and dust cap, 1 canister per box.

【Shelf life】36 months

Ipratropium Bromide Inhaler

Qualitative and quantitative composition  Each canister provides 200 actuations. After priming, each actuation of the inhaler  delivers 21 mcg of ipratropium bromide monohydrate from the valve and delivers 17  mcg of ipratropium bromide monohydrate from the actuator

Therapeutic indications  Ipratropium Pressurised Inhalation is indicated for the regular treatment of reversible  bronchospasm associated with chronic obstructive pulmonary disease (COPD) and  chronic asthma.

Posology and method of administration  For inhalation use.  

Adults (including the elderly): Usually 1 or 2 puffs three or four times daily, although some patients may need up to  4 puffs at a time to obtain maximum benefit during early treatment.  

Children: 6-12 years: Usually 1 or 2 puffs three times daily.  Under 6 years: Usually 1 puff three times daily.  In order to ensure that the inhaler is used correctly, administration should be  supervised by an adult.  

The recommended dose should not be exceeded.  If therapy does not produce a significant improvement, if the patient's condition gets  worse or if a reduced response to treatment becomes apparent, medical advice must be  sought. In the case of acute or rapidly worsening dyspnoea (difficulty in breathing) a  doctor should be consulted immediately.

For detailed information please refer to product leaflet.

SPC for Ipratropium Pressurised Inhalation.pdf



Previous: 
Next: 
Continuous improvement , the pursuit of perfection and to meet regulatory and customer requirements
 

QUICK LINKS

CATEGORIES

CONTACT US INQUIRE NOW
Copyright © 2022 Jewim . All rights reserved.  Sitemap Support By LeadongPrivacy Policy